M1/M2 Phenotype Microglia Regulate Circadian Gene Expression of Glioma
LPS and IL-4 were used to induce BV2 to the M1 and M2 phenotype, respectively. After 24 h, the expression of microglial markers was assessed by qPCR. The results showed that, in LPS-treated BV2 cells, the expression of M1 phenotype markers IL-12 (P < 0.05) and iNOS (P < 0.01) were increased, and in IL-4-treated BV2 cells, the expression of M2 phenotype markers Arg-1 (P < 0.01) and IL-4 (P < 0.01) were increased (Fig. 1A). This result indicates successful induction of the M1 and M2 phenotype.
M1/M2 phenotype BV2 cells were co-cultured with GL261 glioma cells for 48 h. The protein expression of the circadian genes Clock and Bmal1 in GL261 cells was assessed by Western blot. The results showed that the expression level of BMAL1 protein was increased (P < 0.01) in the BV2 (M1) + GL261 group, but significantly reduced (P < 0.01) in the BV2 (M2) + GL261 group. On the contrary, expression the of CLOCK protein was reduced (P < 0.05) in the BV2 (M1) + GL261 group, but amplified (P < 0.05) in the BV2 (M2) + GL261 group (Fig. 1B, C).
M2 Phenotype Microglia Promote Glioma Proliferation
M2 phenotype BV2 cells were co-cultured with GL261 glioma cells and their cell cycle was measured by PI staining after 48 h. The results showed that the population of the GL261 + BV2 (M2) group in the G1 phase was lower than that of the GL261 + BV2 group (P < 0.01), while the population in the G2/M and S phases was higher than that of the GL261 + BV2 group (P < 0.05, P < 0.001; Fig. 2A, B). The survival rate of glioma cells was continuously measured for 5 consecutive days and this showed that the survival rate in the GL261 + BV2 (M2) group was higher than that in the GL261 + BV2 group (P < 0.01, P < 0.001; Fig. 2C). These results suggest that M2 phenotype microglia improve the survival of glioma cells and promote their proliferation.
Down-regulation of Bmal1 Promotes Proliferation and Migration of GL261 Cells
We next knocked down endogenous Bmal1 using a lentiviral shRNA system. The effect of lentiviral interfering sequences was assessed by comparing the expression levels of BMAL1 protein in three groups of cells: the Bmal1 knockdown group (sh-Bmal1) transfected with HBLV-Arntl-shRNA-GFP-PURO, the blank control group (Blank), and the negative control group (sh-NC) transfected with HBLV-GFP-PURO. The results showed that BMAL1 protein expression was reduced in the sh-Bmal1 group (P < 0.05), and there was no difference in expression between the Blank and sh-NC groups (Fig. 3A, B). These results suggest that we successfully integrated the interference sequence of Bmal1 into the genome of GL261 cells.
We evaluated Bmal1-knockdown cells by CCK-8 assay and transwell migration. The CCK-8 results demonstrated that the survival rate in the sh-Bmal1 group was higher than that in control groups (P < 0.001; Fig. 3C). In addition, the results of the transwell assay showed an increase in the number of cells crossing the diaphragm in the sh-Bmal1 group (P < 0.05; Fig. 3D, E). Taken together, down-regulation of the Bmal1 gene promotes the proliferation and migration of GL261 cells in vitro.
miR-7239-3p is Up-regulated in M2 Phenotype Microglia Exosomes
Next, exosomes derived from M2-polarized and unpolarized BV-2 microglia were identified using TEM and Western blot analysis. As shown in Figure 4A, the typical cup-shaped membrane vesicle morphology was observed. Western blot analysis confirmed the expression of the exosome marker CD9 (Fig. 4B), indicating that microglial exosomes were successfully isolated. TargetScan that targets the Bmal1 3’UTR, and miR-7239-3p was selected to predict miRNAs. RT-qPCR was used to quantitate the miR-7239-3p expression level in exosomes. The results showed that the expression of exosomal miR-7239-3p in M2 microglia was significantly up-regulated (Fig. 4C).
To explore how microglia-derived exosomes interact with gliomas, we labeled exosomes with PKH-67 and observed their distribution in gliomas. The results showed that exosomes were evenly distributed in the cytoplasm of glioma cells after incubation for 12 h (Fig. 4D). This suggests that glioma cells are able to take up microglial exosomes, likely by endocytosis. Moreover, this result also provides evidence for the correlation between up-regulated miR-7239-3p expression in glioma cells and the presence of M2 microglial exosomes.
M2 Microglial Exosomes Promote Glioma Progression
After glioma cells were incubated with either unpolarized BV2 exosomes or M2 microglial exosomes, the apoptosis and cell cycle of GL261 cells were assessed by flow cytometry. The results showed that in the GL261 + BV2 (M2) Exosomes group, the early apoptosis, late apoptosis, and total apoptosis were reduced (P < 0.01, P < 0.001, P < 0.001; Fig. 5A, B) and the population of cells in the G1 phase was also reduced (P < 0.01), while the S phase population was increased (P < 0.01; Fig. 5C, D).
Subsequently, colony-forming and CCK8 assays were used to measure the cell proliferation, and transwell and wound-healing assays were used to evaluate invasion and migration, respectively. The results showed that the GL261 + BV2 (M2) Exosomes group displayed and more colonies (P < 0.01; Fig. 5E, H), and showed an increase in the number of cells crossing the diaphragm (P < 0.01; Fig. 5F, I). The cell survival rate in the GL261 + BV2 (M2) Exosomes group was higher (P < 0.001; Fig. 5G). In addition, the percentage wound healing of the GL261 + BV2 (M2) Exosomes group was higher than that of the GL261 + BV2 Exosomes group (P < 0.05; Fig. 5J, L).
RT-qPCR was used to quantitate the RNA expression of Bmal1 and miR-7239-3p in vitro, and Western blot was used to assess the expression of tumor-related proteins. The RT-qPCR results showed that the expression of Bmal1 in the GL261 + BV2 (M2) Exosomes group was reduced (P < 0.001), while the expression of miR-7239-3p was increased (P < 0.001; Fig. 5K). Western blot analysis showed that the expression of BMAL1 and E-Cadherin were reduced in the GL261 + BV2 (M2) Exosomes group (P < 0.05, P < 0.01), while the expression of N-Cadherin and Vimentin were increased (P < 0.05, P < 0.01; Fig. 5M, N).
miR-7239-3p Inhibitor Reverses the Tumor-promoting Effects of M2 Phenotype Microglia Exosomes
In order to establish that miR-7239-3p is an important intermediate molecule in the promotion of glioma progression by M2 microglial exosomes, we examined the effects of an miR-7239-3p inhibitor and miR-7239-3p inhibitor negative control (inhibitor NC) on glioma cells by measuring the growth of GL261 cells and their expression of tumor-related proteins. The results of flow cytometry showed that the population of GL261 cells in early apoptosis and total apoptosis were increased (P < 0.001) in the miR-7239-3p Inhibitor group (Fig. 6A, B), and the number of GL261 cells in the G1 and G2/M phases of this group increased (P < 0.05, P < 0.01), while the number of cells in S phase was reduced (P < 0.001; Fig. 6C, D). These results suggest that miR-7239-3p accelerates glioma proliferation and reduces glioma apoptosis. Intriguingly, miR-7239-3p mainly affected the early apoptosis of GL261 cells, but had little effect on late apoptosis.
The results of colony-forming assays showed that the miR-7239-3p Inhibitor group displayed and fewer colonies (P < 0.05; Fig. 6E, H), indicating weakened cell proliferation. In addition, transwell assays showed a decrease in the number of cells crossing the diaphragm in the miR-7239-3p Inhibitor group (P < 0.01; Fig. 6F, I), indicating reduced invasiveness. Unsurprisingly, CCK-8 assays showed that the cell survival rate in the miR-7239-3p inhibitor group was also lower than that in the control group (P < 0.001; Fig. 6G). And the percentage wound healing in the miR-7239-3p inhibitor group was lower than that in the control group (P < 0.05; Fig. 6J, L).
The RT-qPCR results demonstrated an increase (P < 0.001) in the expression of Bmal1 and decreased expression of miR-7239-3p (P < 0.001) in the miR-7239-3p inhibitor group (Fig. 6K), indicating that miR-7239-3p expression was inhibited. Western blot analysis showed that the expression levels of BMAL1 and E-Cadherin were increased in the miR-7239-3p Inhibitor group (P < 0.01, P < 0.001), while the expression of N-Cadherin and Vimentin were decreased (P < 0.01; Fig. 6M, N).
Negative Correlation Between Bmal1 and miR-7239-3p Expression In Vivo
In order to investigate the role of M2 microglia-derived exosomes in vivo and further explore the molecular function of miR-7239-3p in glioma progression, we established a mouse subcutaneous glioma model and injected M2 or unpolarized microglial exosomes through the tail vein. After the mice were sacrificed, the RNA expression levels of Bmal1 and miR-7239-3p in tumor tissue from each group were measured (Fig. 7). The results showed that the expression of Bmal1 in tumor tissue from the GL261 + BV2 (M2) Exosomes group was reduced (P < 0.001), while the expression of miR-7239-3p was increased (P < 0.001; Fig. 7A). This is in contrast to the results from the GL261 group, where Bmal1 expression was increased (P < 0.001) but miR-7239-3p expression was decreased (P < 0.001; Fig. 7A). Collectively, the correlation analysis illustrated that the expression level of miR-7239-3p was negatively correlated with that of Bmal1 (r = −0.847, P < 0.001; Fig. 7B).
M2 Phenotype Microglial Exosomes Promote Glioma Growth in vivo
We then explored the expression of BMAL1 protein in tumor tissue using IHC. The results showed that the BMAL1 staining area and intensity in tumor tissue were reduced in the GL261 + BV2 (M2) Exosomes group (Fig. 8G), and by statistical analysis, the expression of BMAL1 protein in this group was reduced (P < 0.05, P < 0.001; Fig. 8H). This result is in accordance with our findings from RNA quantitation. This evidence further suggested that M2 phenotype microglial exosomes are likely to affect the expression of miR-7239-3p in vivo, which in turn, affects the downstream regulators by down-regulating the expression of BMAL1 protein.
After glioma injection, changes in the tumor volume and mouse weight were recorded every three days. The results showed that the tumor volume increased faster (P < 0.05) in the GL261 + BV2 (M2) Exosomes group (Fig. 8E). Intriguingly, mouse weight in the GL261 + BV2 (M2) Exosomes group did not significantly increase throughout the study, while mice in the other two groups displayed a significant increase in weight from the day 24 (P < 0.01; Fig. 8F). On the day 30 after glioma injection, we killed the mice, took their pictures (Fig. 8C), and recorded the tumor weight. The results showed that the tumor weight was larger (P < 0.01) in the GL261 + BV2 (M2) Exosomes group (Fig. 8E).
We used HE staining to observe the morphological characteristics of tumor cells in each group, and found apoptosis in glioma tissue by TUNEL assays. The results showed that in the GL261 + BV2 (M2) Exosomes group, the tumor cells were closely arranged with a normal size and clear structure. Both the GL261 group and the GL261 + BV2 Exosomes group displayed reduced cell body size and enlarged gaps, and in addition, nuclear shrinkage and fragmentation were observed in some of the cells (Fig. 8I). TUNEL assay results showed that while a large number of apoptotic cells was observed in the GL261 group and GL261 + BV2 Exosomes group, with apoptosis indexes of 42.93 ± 10.07% and 48.90 ± 7.98%, respectively, while the GL261 + BV2 (M2) Exosomes group showed a reduction in apoptotic bodies (P < 0.001), with an apoptosis index of 19.43 ± 5.09% (Fig. J).